Clinical Trial Update: Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the combination of savolitinib and osimertinib for EGFR-mutant, MET-amplified non-small cell lung cancer; currently active and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Savolitinib (savolitinib)

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING